Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)
First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab
Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)
DRUG: Rituximab
First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab